alexa Release studies from smart hydrogels as carriers for piroxicam and copper(II)-oxicam complexes as anti-inflammatory and anti-cancer drugs. X-ray structures of new copper(II)-piroxicam and -isoxicam complex molecules.
Biomedical Sciences

Biomedical Sciences

Journal of Biomedical Engineering and Medical Devices

Author(s): Tamasi G, Serinelli F, Consumi M, Magnani A, Casolaro M,

Abstract Share this page

Abstract Piroxicam H(2)PIR (H(2)PIR, 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide), [Cu(HPIR)(2)(H(2)O)(2)] previously prepared and tested from this laboratory and at National Institute of Health, National Cancer Institute, Developmental Therapeutic Program, NIH-NCI-DTP, USA [R. Cini, G. Tamasi, S. Defazio, M.B. Hursthouse, J. Inorg. Biochem. 101 (2007) 1140-1152, and references cited therein], [Cu(HMEL)(2)(DMF)] (H(2)MEL, 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; DMF, N,N-dimethylformamide), [Cu(HISO)(2)] (H(2)ISO, 4-hydroxy-2-methyl-N-(5-methylisoxazol-3-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide), and [Cu(HTEN)(2)(H(2)O)(2)] (H(2)TEN, 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide), were loaded on CMH2 hydrogel (co-1:10-poly(N-methacryloyl-L-histidine-co-N-isopropylacrylamide) cross-linked with N,N'-ethylene-bis-acrylamide (EBA) 2\%) and the kinetics of release of Cu-HPIR species in several media were studied. The release of Cu(HPIR)(2) in DMSO from CMH2 hydrogel after swelling and loading from DMSO followed a diffusion controlled process. The release of Cu(HPIR)/Cu(HPIR)(2) from dried CMH2 hydrogel after swelling and loading from THF solution, then soaking into water/DMSO 95:5 v/v (pH 5.6) followed a relaxation controlled and diffusion controlled mechanism. The amount of Cu(HPIR)(2) released in the medium reached 0.03 microg Cu/mg gel/mL, i.e. ca 0.8 microM within 48 h that compares well with the IC(50) values reported for metal based drugs like carboplatin (diammino(1,1-cyclobutandicarboxylato)platinum(II)) against certain human tumor cell lines. The release studies performed by monitoring both the absorbance values at 362 nm (sensitive to metal-bound HPIR(-)) and the content of Cu via AAS, showed an excellent agreement with the Cu(HPIR)(2) or Cu(HPIR)(2) stoichiometry, depending on the delivery medium. Corresponding studies were performed for other Cu(oxicam-H)(2) species in different delivery media. This article was published in J Inorg Biochem and referenced in Journal of Biomedical Engineering and Medical Devices

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords